Clinical trials: New Onset Type-1 Diabetes
Type 1 Diabetes, type1diabetes
Reducing Innate Inflammation in New Onset Type 1 Diabetes
This study aims to determine whether Lactiplantibacillus plantarum 299v (Lp299v) supplementation will reduce systemic inflammation and prolong residual beta cell function in individuals newly diagnosed with Type 1 diabetes.
- Conditions
- Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
- Trial name
- NCT04335656
- Testing
- Lactiplantibacillus plantarum
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Medical College of Wisconsin
Type 1 Diabetes
The Steno Free Trial: AID to Adults with New-onset of Type 1 Diabetes
Since the introduction of insulin therapy 100 years ago, significant progress has continuously been made in the treatment of people with type 1 diabetes.
- Trial name
- NCT06586632
- Testing
- AID technology, CGM
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Type 1 Diabetes
Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Clinically, the ability to slow or prevent beta cell demise can prevent or improve the course of type 1 diabetes. The immune-mediated destruction of beta cells that is an apparent major pathological basis for the disease, has led…
- Trial name
- NCT02218619
- Testing
- Tauroursodeoxycholic Acid (TUDCA)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Robin Goland, MD
Type 1 Diabetes
New Onset Type 1 Diabetes: Role of Exenatide
There are many recent advances in insulin treatment of type 1 diabetes, however after a meal sugars are always a concern. There is a drug Exenatide (Byetta) which is FDA approved to treat people with type 2 diabetes which helps…
- Trial name
- NCT01269034
- Testing
- Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
The purpose of this study is to determine the key factors influencing insulin sensitivity in type 1 diabetes (T1DM) and maturity onset diabetes of the young, type 2 (MODY2).
- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Trial name
- NCT02971202
- Testing
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Type 1 Diabetes
Baricitinib in New-onset Type 1 Diabetes
Type 1 diabetes (T1D) results from the killing of insulin-producing pancreatic beta cells by cells of the immune system. The study aims to slow the progressive, immune-mediated loss of insulin-producing beta cells that occurs…
- Trial name
- BANDIT (NCT04774224)
- Testing
- Baricitinib
- Where
- 4 sites in Australia
- Volunteers
- 91 people
- Sponsor
- St Vincent's Institute of Medical Research
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Minimal Islet Transplant at Diabetes Onset
This is a prospective phase 2, single-arm, mono-center pilot study. It has been designed to investigate whether giving the combination therapy consisting of minimal islet transplantation (1500 EIQ/Kg body weight), Thymoglobulin®…
- Trial name
- MITO (NCT02505893)
- Testing
- Human pancreatic islet, ATG, Pegylated G-CSF
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Ospedale San Raffaele
New Onset Type 1 Diabetes Mellitus
A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
The rationale for the study is to determine if Campath-1H can be used in patients recently diagnosed with type I DM, to induce a state of immunological unresponsiveness such that subjects can safely preserve beta cell mass and…
- Trial name
- NCT00214214
- Testing
- Campath 1H® (Alemtuzumab)
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Type 1 Diabetes
Anti-Interleukin-1 in Diabetes Action
A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the insulin production in patients with new onset Type 1 diabetes.
- Trial name
- AIDA (NCT00711503)
- Testing
- anakinra, saline
- Where
- 17 sites in Denmark, Germany and 5 more
- Volunteers
- 69 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 1 Diabetes
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
- Trial name
- SAFEGUARD (NCT07187531)
- Testing
- High Dose SAB-142, Low Dose SAB-142
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 159 people
- Sponsor
- SAb Biotherapeutics, Inc.
Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100…
- Trial name
- NCT05743244
- Testing
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type1diabetes
Phenotypic and Genotypic Characterization of New-onset Type I Diabetes
The goal of DIATAG study is the identification of biomarkers of T1D evolution in a pediatric cohort.
- Trial name
- DIATAG (NCT04007809)
- Testing
- Glucagon
- Where
- Belgium
- Volunteers
- 98 people
- Sponsor
- Université Catholique de Louvain
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Ketoacidosis, Diabetic
Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis
This is a phase II trial in individuals who have been diagnosed with type 1 diabetes within the previous 12 months and suffered from diabetic ketoacidosis at onset of disease.
- Trial name
- UCMSCDKA (NCT02763423)
- Testing
- umbilical cord mesenchymal stem cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Diabetes Mellitus, Type 1
Proleukin and Rapamune in Type 1 Diabetes
This is a phase I trial in individuals who have been diagnosed with type 1 diabetes within the previous 3-48 months. The study is testing whether two immune system modifying drugs are safe when used in combination and if they…
- Trial name
- NCT00525889
- Testing
- IL-2, Rapamycin
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
Immune Profile in Subjects With New Onset Type 1 Diabetes
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed…
- Trial name
- NCT02801942
- Testing
- Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, Peripheral blood collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.
- Trial name
- TN09 (NCT00505375)
- Testing
- CTLA-4 Ig
- Where
- 13 sites in United States, Canada
- Volunteers
- 112 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects…
- Trial name
- ATG-GCSF (NCT02215200)
- Testing
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF)
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)